RxDoctor Payments Data

John Howell, MD

Internal Medicine · Mobile, ALNPI 1871518225

Payments from drug & device makers

$1,857in general payments, 2019–2025

Across 65 payments — averaging $28.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$678
  • Novo Nordisk$259
  • Johnson & Johnson$212
  • Sanofi$115
  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$106
  • Pfizer$77
  • plus $410 from 13 others

What the payments were for

  • Food & beverage$1,857100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,857 in reported general payments places this provider in the 70th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$51,120
Medicare patients
85
Services billed
982

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide37$49,612
RybelsusSemaglutide30$37,536
MounjaroTirzepatide28$30,987
JardianceEmpagliflozin27$21,150
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$17,734
Spiriva RespimatTiotropium Bromide16$9,614
ShingrixVaricella-Zoster Ge/As01b/Pf29$6,062
Breo ElliptaFluticasone/Vilanterol14$5,700
Lantus SolostarInsulin Glargine,hum.Rec.Anlog69$4,900
Atorvastatin Calcium362$4,765
Albuterol Sulfate HfaAlbuterol Sulfate114$4,260
Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med34$2,892
Montelukast Sodium205$2,471
Omeprazole115$2,230
Diltiazem 24hr Er (Cd)Diltiazem Hcl16$2,152

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$259$87,14967 claims
Lilly USA, LLCMounjaro$28$30,98728 claims
GSKTrelegy Ellipta, Shingrix, Breo Ellipta$37$29,49665 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →